Berlin, April 23-24, 2012

Since its successful launch in 2007, the Charité Entrepreneurship Summit has become an international forum for participants and speakers coming from various professional backgrounds in medicine, life sciences, and in entrepreneurship.
On April 23-24, 2012, the Charité Foundation will hold the fifth “Charité Entrepreneurship Summit” in Berlin. Once again researchers, clinicians, and doctoral students present fresh ideas and learn from academic entrepreneurs, investors, and business developers.


If you have any further questions, please do not hesitate to contact our project manager, Mrs Katharina Stoecker, by telephone +49 30 450570-508 or send us an email.

See some of our Speakers from 2011 below. If you want to register for our Summit 2012 click here.


Contact

If you have any further questions, please do not hesitate to contact our project manager, Mrs Katharina Stoecker, by telephone +49 30 450570-508 or email.

Peter Thiel


Co-Founder and former CEO, PayPal; Early Investor, Facebook; Founder and Partner, The Founder's Fund; Founder and Benefactor, Thiel Foundation; President, Clarium Capital, San Francisco/ USA

Peter Thiel, who was born in Germany, is one of the most successful investors in Silicon Valley. His role as an early angel investor for the start-up company Facebook was featured in the motion picture "The Social Network". He is also an innovative philanthropist ("Thiel Fellowships") and has been, since his student days at Stanford, one of the most outspoken libertarians in the US. Vita

Peer Schatz


CEO, QIAGEN GmbH, Hilden/ Germany

Peer Schatz is a serial entrepreneur and has been a leader at Qiagen starting in 1993. Since he joined Qiagen, the company has grown from 30 to 3,600 employees and increased its revenues from US$ 2 million to more than US$ 1 billion. He was the first German entrepreneur to list his company on the NASDAQ. Vita

Hanson S. Gifford


Partner and CEO, The Foundry LLC, Menlo Park/ USA

Hanson Gifford has led The Foundry in all its activities since 1998 and developed it into the premier medical device incubator in the US. The companies developed and funded by The Foundry have generated in excess of US$ 1 billion in value for their founders and investors. Earlier, he distinguished himself as a serial medtech entrepreneur in the US and in Bavaria. He is a prolific inventor, with 115 issued and 200 pending US patents to his name. Vita
 

Axel Ullrich


Serial Entrepreneur (SUGEN, Axxima Pharmaceuticals, U3 Pharma, Kinaxo) and Director, Max Planck Institute of Biochemistry; Director, Singapore Onco Genome Laboratory, Martinsried/ Germany

Axel Ullrich is one of the most distinguished German biochemists, and he is also among the most successful biotech entrepreneurs in the country. He developed, among other drugs, the monoclonal antibody Trastuzumab (trade name Herceptin), now used against breast cancer worldwide. Vita